Journal of Internal Medicine最新文献

{"title":"Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry","authors":"Lotta Stenberg,&nbsp;Björn Pilebro,&nbsp;Intissar Anan,&nbsp;Jorge Mejia Baranda,&nbsp;Kristin Samuelsson,&nbsp;Per Eldhagen,&nbsp;Rolf Backlund,&nbsp;Jonas Wixner","doi":"10.1111/joim.70020","DOIUrl":"10.1111/joim.70020","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hereditary transthyretin (ATTRv) amyloidosis was first described in Sweden in the late 1960s. Selected patient data have been collected since then and have now been transferred to a national quality registry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is the first report from SveATTR—a longitudinal Swedish web-based registry open for <i>TTR</i> variant carriers and patients with ATTR amyloidosis. The registry covers basic background information, as well as relevant clinical follow-up measures and data on disease-modifying therapies. Data from all ATTRv amyloidosis patients registered through December 2022 were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 1055 patients were included, of whom 65% were males and 95% carried the V30M variant. Median age of onset was 64 years, and 79% had a late disease onset (≥50 years). Eighty-seven percent of the patients had peripheral polyneuropathy at onset, whereas 10% had cardiac symptoms, 8% had visual disturbances, and 6% had gastrointestinal symptoms. A total of 159 patients had undergone liver transplantation, and 233 had received a disease-modifying drug. Improved survival was seen for transplanted patients and for patients on drug therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This report highlights the importance of SveATTR for further characterization of the Swedish ATTRv amyloidosis population as well as for evaluating the efficacy of disease-modifying therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 5","pages":"478-488"},"PeriodicalIF":9.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxidized high-density lipoprotein associates with cardiometabolic dysfunction in coronary artery disease and acute coronary syndrome","authors":"Benjamin Sasko,&nbsp;Nikolaos Pagonas,&nbsp;Martin Christ,&nbsp;Jan Wintrich,&nbsp;Oliver Ritter,&nbsp;Christian Ukena,&nbsp;Innas Sultana,&nbsp;Simin Delalat,&nbsp;Ibrahim El-Battrawy,&nbsp;Theodoros Kelesidis,&nbsp;Nazha Hamdani","doi":"10.1111/joim.70019","DOIUrl":"10.1111/joim.70019","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>High-density lipoprotein (HDL) function, rather than its concentration, plays a crucial role in the development of coronary artery disease (CAD). Diminished HDL antioxidant properties, indicated by elevated oxidized HDL (nHDL_ox) and diminished paraoxonase-1 (PON-1) activity, may contribute to vascular dysfunction and inflammation. Data on these associations in CAD patients, including acute coronary syndrome (ACS), remain limited. The aim of this study is to assess the association of oxidized HDL with PON-1 activity, oxidized low-density lipoprotein (LDL), vascular cell adhesion molecule-1 (VCAM-1), IL-6 levels, and nitric oxide (NO) production as markers of vascular health.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We assessed HDL function in three groups: 90 CAD patients, 90 healthy controls, and 90 ACS patients. HDL antioxidant function was measured using a validated biochemical assay to quantify oxidized HDL (nHDL_ox). Plasma PON-1 activity, oxidized LDL, VCAM-1, IL-6, and NO production were also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ACS patients had nHDL_ox levels 140% higher than healthy controls (<i>p</i> &lt; 0.001). Higher nHDL_ox levels were significantly linked to vascular inflammation, reflected by elevated VCAM-1 levels. Additionally, a reduced PON-1 activity indicates an impaired antioxidant protection in ACS patients. Finally, oxidized LDL levels were elevated, and NO production was reduced, suggesting impaired vascular function.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HDL_ox levels are highest in patients with ACS. Patients with stable CAD have higher levels than healthy controls. Correspondingly, the parameters of HDL function measured in this study, which all indicate a loss of HDL's atheroprotective function, correlate with these findings. Our study establishes a novel mechanistic pathway linking oxidized HDL to the presence of an ACS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical trial registration</h3>\u0000 \u0000 <p>DRKS00014037</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 5","pages":"464-477"},"PeriodicalIF":9.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145028602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors reply: Standard and advanced echocardiographic study of patients with Paget's disease of bone: Evidence of a Pagetic heart disease?","authors":"Alfonso Giaquinto,&nbsp;Veronica Abate,&nbsp;Anita Vergatti,&nbsp;Riccardo Muscariello,&nbsp;Adelaide Iervolino,&nbsp;Martina Pucci,&nbsp;Guido Cavati,&nbsp;Filippo Pirrotta,&nbsp;Gianpaolo De Filippo,&nbsp;Roberta Esposito,&nbsp;Lanfranco D'Elia,&nbsp;Daniela Merlotti,&nbsp;Luigi Gennari,&nbsp;Domenico Rendina","doi":"10.1111/joim.70013","DOIUrl":"10.1111/joim.70013","url":null,"abstract":"<p>To the editor,</p><p>We recognize the suggestion displayed by Famularo [<span>1</span>] and by Wu et al.[<span>2</span>] and appreciate the editor's opportunity to clarify our evidences. In our cross-sectional paper, we suggested the occurrence of a specific heart impairment in patients with Paget's disease of bone (PDB), namely, Pagetic heart disease, characterized by systo-diastolic dysfunction with higher left ventricular filling pressures, lower ejection fraction, concentric left ventricular remodeling, and a higher prevalence of cardiac valve sclerosis and calcifications.[<span>3</span>] One of the strengths of the study was the strict inclusion and exclusion criteria, which ruled out common cardiovascular diseases.[<span>3</span>]</p><p>Dr. Famularo suggested that our findings can be affected by bias, such as other unrecognized cardiac conditions, like transthyretin cardiac amyloidosis (TTA). However, it must be noted that all PDB patients underwent a Tc-99m–methylene diphosphonate (MDP) scintigraphy, both to diagnose and classify the condition.[<span>4</span>] Currently, non-biopsy diagnostic criteria for TTA include Tc-99m–MDP scintigraphy in diagnostic algorithm,[<span>5</span>] because its 100% negative predictive value.[<span>6</span>] Consequently, TTA could be excluded according to negative results in cardiac accumulation of Tc-99m–MDP during scintigraphy.</p><p>To further address Dr. Famularo's concerns and support the evidence of a Pagetic heart disease, we conducted an analysis of a small cohort of our patients diagnosed with transthyretin amyloidosis (TTA) and compared their clinical characteristics with PDB patients’ (Table 1), age- and sex-matched. As reported in the position statement of the ESC Working Group on Myocardial and Pericardial Diseases,[<span>7</span>] there are established echocardiographic criteria for non-invasive diagnosis of TTA as unexplained left ventricular thickness (≥12 mm) plus more than two of the following echocardiography findings: Grade 2 or worse diastolic dysfunction; reduced tissue Doppler systolic, early diastolic, and late diastolic wave velocities (&lt;5 cm/s); and decreased global longitudinal left ventricular strain (absolute value &lt; −15%). These features closely resemble those observed in our cohort of patients with TTA, whereas none of our patients with PBD exhibited such characteristics, despite presenting with a specific form of cardiac involvement.</p><p>In the second letter, Wu et al. raised some concerns, such as hint for predictive values and cut-off parameters for the Pagetic heart disease to look for in prospective studies; the contradiction in the found significance in the left ventricle ejection fraction but not in the global longitudinal strain in Table 3 [<span>3</span>]; and lastly, the suggestion for evaluation of segmental strain and myocardial work.</p><p>We greatly appreciated the first comment, as it gives us the opportunity to introduce the work we are currently con","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 5","pages":"528-530"},"PeriodicalIF":9.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between antibiotic use and the onset of giant cell arteritis and polymyalgia rheumatica: A nested case–control study from E3N-European Prospective Investigation into Cancer and Nutrition","authors":"Lucas Pacoureau,&nbsp;François Barde,&nbsp;Amandine Gelot,&nbsp;Alexis Elbaz,&nbsp;Agnès Fournier,&nbsp;Yann Nguyen,&nbsp;Raphaèle Seror","doi":"10.1111/joim.70000","DOIUrl":"10.1111/joim.70000","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To assess the association between infections, assessed by antibiotic reimbursement, and the occurrence of giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a nested case–control study from the French cohort E3N-European Prospective Investigation into Cancer and Nutrition, which has followed 98,995 women since 1990. Cases, defined as patients who developed GCA and/or PMR during follow-up, were matched with 20 controls on age and vital status. Infections prior to index date, defined by ≥1 antibiotic reimbursement on the medication claims reimbursement database, were compared between groups using conditional logistic regression models, adjusted for potential confounders. Different time periods before the index date and different antibiotic classes were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 428 GCA/PMR cases (113 GCA, 232 PMR, 83 undefined) were compared to 8560 matched controls. Compared to controls, GCA/PMR cases had higher odds to have any infection in the [0–24] months prior to index date (aOR [95% CI] 1.22 [1.00–1.51]). Considering the 6-month periods prior to index date, the association was stronger when close to index date (1.18 [0.94–1.47]; 0.95 [0.75–1.19] for [0–6] and [18–24] months, respectively). This association was only found among GCA cases (1.63 [1.08–2.48] for [0–24] months), but not among PMR cases. Quinolone reimbursements were the most associated with subsequent GCA (2.07 [1.23–3.49] for [0–12] months).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Compared to controls, GCA patients were at higher risk of having used antibiotics in the 24 months prior to the diagnosis. Infections or a disbalanced microbiome could act as a trigger of the disease, although a reverse causation bias cannot be excluded.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 5","pages":"424-437"},"PeriodicalIF":9.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of remission and relapse in retroperitoneal fibrosis","authors":"Milena Bond,&nbsp;Alessandra Bettiol,&nbsp;Eugenia Accorsi Buttini,&nbsp;Giorgio Trivioli,&nbsp;Giulia Palazzini,&nbsp;Ilaria Fibbi,&nbsp;Michelangelo Tesi,&nbsp;Edoardo Biancalana,&nbsp;Christian Dejaco,&nbsp;Giacomo Emmi,&nbsp;Augusto Vaglio","doi":"10.1111/joim.70017","DOIUrl":"10.1111/joim.70017","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>In retroperitoneal fibrosis (RPF), glucocorticoids (GC), alone or in combination with immunosuppressive agents, induce remission in 80%–90% of patients but up to two thirds of them relapse. There is limited knowledge on outcome predictors in RPF. We aimed to identify clinical, laboratory and imaging predictors of remission and relapse in RPF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included consecutive RPF patients treated with 6–9-month courses of GC with/without immunosuppressive agents. Baseline and post-treatment computed tomography, magnetic resonance imaging and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET) were assessed. The potential predictive value of the examined parameters as predictors of remission and time-to-relapse was analysed using logistic and Cox regression models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 152 patients screened, 115 were included. Of them, 101 (87.8%) achieved remission a median of 4 months (interquartile range 3–5) after starting treatment. At multivariable analysis, smoking (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.11–0.99) and atypical RPF localization (e.g., pelvic) (OR 0.11, 95% CI 0.02–0.52) were negatively associated with remission, whereas pre-treatment ¹⁸F-FDG-PET activity was positively associated (OR 11.51, 95% CI 1.35–98.20). A median of 33 months (17–57) after treatment initiation, 42% patients relapsed (median time from remission to relapse, 14 months [8–26]). Thoracic vessel involvement and positive ¹⁸F-FDG-PET at the end of treatment independently predicted relapse (hazard ratio [HR] 2.61, 95% CI 1.19–5.68 and HR 3.47, 95% CI 1.54–7.82, respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Metabolic activity of RPF at ¹⁸F-FDG-PET is an important predictor of remission and relapse. Smoking and atypical localization are negatively associated with remission, whereas thoracic aorta involvement is associated with relapse risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 5","pages":"438-449"},"PeriodicalIF":9.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal insights into the natural history of Type 2 diabetes among Koreans: A 20-year community-based prospective cohort study","authors":"Wonsuk Choi,&nbsp;Joon Ho Moon,&nbsp;Hun Jee Choe,&nbsp;Howard H. Chang,&nbsp;Dimple Kondal,&nbsp;K. M. Venkat Narayan,&nbsp;Nam H. Cho","doi":"10.1111/joim.70010","DOIUrl":"10.1111/joim.70010","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the natural history of diabetes mellitus (DM) based on metabolic phenotypes of prediabetes in a community-based prospective study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Individuals aged 40–69 years without DM were followed for 20 years. Glycemic parameters, including the 75 g oral glucose tolerance test, were assessed at baseline and biennially thereafter. Markov models were used to estimate each glycemic state's annual transition probabilities and average total length of residence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 7,676 participants without DM, 205 had isolated impaired fasting glucose (iIFG), and 1,753 had impaired glucose tolerance (IGT) at baseline. During the 17.5 years of follow-up, 2,313 (30.1%) cases of DM occurred. The annual transition to DM for those with iIFG was 7.7% (95% confidence interval [CI] 6.9, 8.5) and 6.9% (95% CI 6.6, 7.3) for those with IGT. In the normoglycemia ↔ iIFG → DM model, the total length in normoglycemia was 49.4 years (95% CI 47.0, 52.1), and the length in iIFG was 6.3 years (95% CI 5.9, 6.8). In the normoglycemia ↔ IGT → DM model, the total length in normoglycemia was 34.0 years (95% CI 32.4, 35.4), and the length in IGT was 11.9 years (95% CI 11.1, 12.5).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Individuals remained normoglycemic for long periods. However, the progression to DM occurs rapidly once prediabetes develops, regardless of the metabolic phenotype.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 4","pages":"336-348"},"PeriodicalIF":9.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study","authors":"Minjeong Jeon,&nbsp;Yongtai Cho,&nbsp;Sungho Bea,&nbsp;Wonkyoung You,&nbsp;Sung Kweon Cho,&nbsp;Seungho Ryu,&nbsp;Yoosoo Chang,&nbsp;Ju-Young Shin","doi":"10.1111/joim.70012","DOIUrl":"10.1111/joim.70012","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Type 2 diabetes mellitus (T2DM) and gout are associated with an increased risk of cardiovascular events. Despite the approval for the secondary prevention of cardiovascular diseases by the United States Food and Drug Administration in 2023, evidence regarding the effectiveness of colchicine among T2DM population remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>We aimed to evaluate the association between the use of colchicine and the risk of major adverse cardiovascular events (MACE) among patients with gout and T2DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a nationwide, population-based cohort study with active comparator, new-user design using nationwide claims data of South Korea (2010–2022). Patients with T2DM and gout who initiated colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) from 2011 to 2022 were included. The primary outcome was MACE (myocardial infarction, ischemic stroke, and cardiovascular death). Secondary outcomes were each individual components of primary outcome and hospitalization due to heart failure. As-treated approach with 30-day grace period was applied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Before propensity score (PS) matching, 13,019 colchicine users and 111,594 NSAIDs users were included in the study cohort (mean age, 65.5 vs. 62.9; 35.0% vs. 29.8% female). After 1:2 PS matching, 12,908 colchicine users and 25,816 NSAIDs users remained (mean age, 65.7 vs. 65.7 years; 35.2% vs. 35.1% female). The PS-matched hazard ratio for MACE was 0.94 (95% confidence interval 0.65–1.36), and all secondary outcomes also resulted in null findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Use of colchicine does not significantly reduce the risk of MACE compared with NSAIDs in a real-world population with T2DM and gout in South Korea between 2011 and 2022.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 6","pages":"604-616"},"PeriodicalIF":9.2,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inter-organ crosstalk: The kidney's role in systemic health and disease","authors":"Carmine Zoccali,&nbsp;Rajiv Agarwal,&nbsp;Francesca Mallamaci,&nbsp;Kitty J Jager,&nbsp;Vianda Stel,&nbsp;Mehmet Kanbay,&nbsp;Carol Pollock,&nbsp;Kamyar Kalantar-Zadeh,&nbsp;Claudio Ronco,&nbsp;Raymond Vanholder","doi":"10.1111/joim.70015","DOIUrl":"10.1111/joim.70015","url":null,"abstract":"<p>This review elucidates the critical role of inter-organ crosstalk in systemic health, focusing on the kidney's interactions with the heart, bone marrow, lung, liver, intestine, bone-vascular, and nervous system. These interactions are vital for maintaining physiological homeostasis and are mediated by hormones, cytokines, and metabolites. The kidney's role in these networks is pivotal, as dysfunction can exacerbate systemic diseases, highlighting the need for integrated therapeutic strategies. Chronic kidney disease and acute kidney injury serve as key examples of how kidney dysfunction impacts other organs, leading to complex disease states. The central idea is that the kidney functions within a network of physiological processes, influencing and being influenced by other organs. This review provides an overview of the mechanisms underlying kidney-related inter-organ communication, emphasizing the significance of these interactions in disease progression. We explore how advanced computational models and multi-omics approaches can enhance our understanding of these complex networks, paving the way for precision medicine. The insights derived from this work underscore the potential for future research in developing innovative treatments that target these intricate pathways. By fostering interdisciplinary collaboration and leveraging emerging technologies, we aim to address the multifaceted nature of systemic diseases, offering new avenues for therapeutic intervention. This review represents a paradigm shift from reductionist to integrative approaches, emphasizing the importance of systemic balance and adaptation in human health, and sets the stage for future exploration into the interconnectedness of body systems.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 5","pages":"368-391"},"PeriodicalIF":9.2,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regarding: Standard and advanced echocardiographic study of patients with Paget's disease of bone: Evidence of a pagetic heart disease?","authors":"Huihui Wu,&nbsp;Lihong Wang,&nbsp;Dong Wang","doi":"10.1111/joim.70014","DOIUrl":"10.1111/joim.70014","url":null,"abstract":"<p>Dear Editor,</p><p>We read with enthusiasm the article [<span>1</span>] comparing standard and advanced (speckle-tracking) echocardiographic parameters measured in patients with Paget's disease of bone (PDB) and would like to bring the following comments.</p><p>First, Giaquinto et al. present a multicenter case–control study of patients with PDB and normal controls who underwent very detailed echocardiographic analyses. Although the analyses are detailed, these findings are mainly descriptive and do not necessarily guide practice. The authors may need to evaluate the predictive value of outcomes and prognosis independently among the standard and advanced echocardiographic parameters in the populations [<span>2</span>]. The optimal cut-off value for myocardial work and speckle-tracking parameters in receiver operating characteristic curve analysis should also be applied to help come up with predictive parameters [<span>3</span>].</p><p>Second, no significant difference was observed in global longitudinal strain, whereas the left ventricle ejection fraction (LVEF) was significantly lower between the groups in Table 3 (<i>p</i> &lt; 0.05). However, left ventricle global longitudinal strain is a more sensitive method than LVEF for diagnosing mild systolic dysfunction, applying to patients suspected of having heart failure with normal LVEF [<span>4</span>], which is inconsistent with the results in the study.</p><p>In addition, global longitudinal strain and global work efficiency were significantly lower in patients with PDB than those in controls. In fact, left ventricle was divided into 18 segments for the exploration of the distribution of regional, however, segmental strain and myocardial work were not evaluated, which added value to explore the distribution of myocardial impairment [<span>4, 5</span>].</p><p><b>Huihui Wu</b> and <b>Dong Wang</b>: Conception and design. <b>Huihui Wu</b> and <b>Lihong Wang</b>: Writing of the manuscript. All authors have reviewed and approved the final version of the manuscript.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 5","pages":"526-527"},"PeriodicalIF":9.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes”","authors":"","doi":"10.1111/joim.70009","DOIUrl":"10.1111/joim.70009","url":null,"abstract":"<p>Yen FS, Hung YM, Huang JY, Hsu CC, Cheng WY, Hwu CM, et al. Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes. J Intern Med. 2025;297(5):532-542. https://doi.org/10.1111/joim.20077</p><p>In the originally published article, the affiliation for Jing-Yang Huang was incorrectly listed.</p><p>The incorrect affiliation was:</p><p>“6 Institute of Medicine, Chung Shan Medical University, Taichung City, Taiwan”</p><p>The correct affiliations for Jing-Yang Huang are:</p><p>“6 Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan; Department of Medical Research, Chung Shan Medical University Hospital, Taichung, 402, Taiwan.”</p><p>We apologize for this error.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 4","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}